Company Overview and News

Pintaras Jaya, IOI Corp, Prestariang, Ibraco, Guan Chong and BP Plastics

2016-11-18 theedgemarkets
KUALA LUMPUR (Nov 18): Based on corporate announcements and news flow today, stocks in focus on Monday (Nov 21) may include Pintaras Jaya Bhd, IOI Corp Bhd, Prestariang Bhd, Ibraco Bhd, Guan Chong Bhd and BP Plastics Holding Bhd.

KLCI edges up in early trade in line with regional rally, gains seen capped

2016-06-29 theedgemarkets
KUALA LUMPUR (June 29): The FBM KLCI edged up in early trade trade today in line with the overnight rally at most global markets and regional uptick today but gains are seen limited.

KLCI pares loss as June window dressing cushions decline

2016-06-28 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI pared some of its losses at mid-morning today as end-June window dresssing cushioned its decline despite sharp losses elsewhere in the region.

AirAsia, AAX, AWC, Tek Seng, TSR Capital, KSTB, BP Plastics and Pharmaniaga

2016-02-16 theedgemarkets
KUALA LUMPUR (Feb 15): Based on corporate announcements and news flow today, companies likely to be in focus next Tuesday (Feb 16) include AirAsia, AirAsia X (AAX), AWC, Tek Seng, TSR Capital, KSTB, BP Plastics and Pharmaniaga. AirAsia Bhd saw better operating performance for the quarter ended Dec 31, 2015 (4QFY15), reporting a 12% year-on-year (y-o-y) increase in its number of passengers to 13.5 million, from 12.

BP Plastics 'buy',MBSB 'neutral',Astro 'outperform'

SIMILAR to other export-based plastic packagers, BP Plastics Holding Bhd (BPP) is riding on the wave of higher revenue driven by export sales, which made up 79% of total sales, benefitting from a depreciating ringgit

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...